31 results about "FKBP" patented technology

Methods and compositions for the rapid and reversible destabilizing of specific proteins using cell-permeable, synthetic molecules are described. Stability-affecting proteins, e.g., derived from FKBP and DHFR proteins are fused to a protein of interest and the presence or absence of the ligand is used to modulate the stability of the fusion protein.

Provided herein are methods for identifying a compound that modulates a Ryanodine receptor (Ryr). Fluorescence resonance energy transfer between an FKBP bound to an RyR and fluorescent derivatives of RyR binding partners (e.g., calmodulin) or domain-peptide biosensors is used to provide a readout dependent on the RyR functional state. The methods permit measurement of RyR present in a permeabilized cell or in a purified membrane.

A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I,wherein, R, R1, R2, R3 and X are as defined herein.

The present invention provides methods of limiting or preventing decreased levels of RyR2-bound FKBP 12.6 in a patient, methods of treating or preventing exercise-induced cardiac arrhythmias in a patient, and methods of preventing exercise-induced sudden cardiac death in a patient. Use of JTV-519 in these methods is also provided. The present invention also provides a method of identifying a substance for preventing exercise-induced sudden cardiac death, and a substance identified by the method. Also provided are methods of preventing exercise-induced sudden cardiac death by administering these substances. Additionally, the present invention provides methods for the synthesis of JTV-519, radiolabeled JTV-519, and 1,4-benzothiazepine intermediates and derivatives.

The invention discloses a nano-switch molecule and solid tumor-targeted CAR-T cells controlled and activated by the same. The solid-tumor-targeted CAR-T cells are prepared by the following steps: 1) Preparation of nano-switch molecules: double emulsification-volatile 2) Construction of an assembled CAR-T plasmid: the T2A element, FRB, FKBP sequence and the ScFv segment targeting solid tumors were introduced into the CAR-T plasmid by genetic recombination ; 3) Preparation of assembled CAR-T cells: transfection of assembled CAR-T plasmids into T lymphocytes; 4) Preparation of solid tumor-targeted CAR-T cells: assembly of CAR-T cells endocytosis of nano-switch molecules. In the present invention, by using tumor-targeting nanoparticles to load switch molecules, the switch molecules can be specifically aggregated in tumor tissues, and the switch molecules are connected to FKBP and FRAP of CAR-T, so that the two parts of CAR-T can be combined to have attack activity. It can fundamentally solve the problem of off-target effects of CAR‑T cells.

The invention discloses the cloning, expression and uses of a chimeric fusion protein with superior chaperone and folding activities compared to the wild type chaperones. This invention relates to a chimeric fusion protein encoded by a recombinant DNA molecule comprising nucleotide sequences coding for a polypeptide binding segment of a non-human chaperone protein and nucleotide sequences coding for an FK506 binding protein (FKBP) or an FK506-binding-protein-like domain (FKBP-like domain). In particular, this invention relates to a chimeric fusion protein encoded by a recombinant DNA molecule comprising nucleotide sequences coding for a polypeptide binding segment of a non-human chaperone protein and nucleotide sequences coding for a human FKBP type peptidyl-prolyl-cis / trans isomerase (PPIase), methods of producing these chimeric fusion proteins and their uses as folding helpers in the production of other proteins and in the process of the production of vaccines or pharmaceuticals, and as folding helpers for performing immunoassays.

Analogs of FK506 that do not bind FKBP-12 have been found to effectively promote nerve cell growth and regeneration, thereby speeding functional recovery of damaged nervous tissue and axonal regeneration without causing immunosuppression.

The present description relates to anti-Thermus thermophilus SlyD FKBP domain antibodies and methods of using the same.

The inventors have determined that increasing the expression level or activity of FKBP-L polypeptide in a subject, which can be provided by expression of nucleic acids encoding FKBP-L or by providing FKBP-L polypeptides to a subject is advantageous for use in the treatment of obesity and obesity-related disorders. In particular increased expression or activity of FKBP-L polypeptide in a subject may be used to treat excessive weight gain (which can be characterised as obesity), glucose intolerance, diabetes and metabolic syndrome, which are closely linked to obesity and insulin resistance. FKBP-L can also be used as a biomarker for obesity and obesity-related disorders.